These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8870590)

  • 1. Pharmaceutical representatives. Guidelines exist on making effective use of time spent with representatives.
    Tiner R
    BMJ; 1996 Oct; 313(7061):881. PubMed ID: 8870590
    [No Abstract]   [Full Text] [Related]  

  • 2. Physicians, pharmaceutical representatives, and patients: who really benefits?
    Westfall JM
    J Fam Pract; 2000 Sep; 49(9):817-9. PubMed ID: 11032206
    [No Abstract]   [Full Text] [Related]  

  • 3. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study.
    Watkins C; Moore L; Harvey I; Carthy P; Robinson E; Brawn R
    BMJ; 2003 May; 326(7400):1178-9. PubMed ID: 12775618
    [No Abstract]   [Full Text] [Related]  

  • 4. Residents and pharmaceutical representatives.
    Lexchin J
    Can Fam Physician; 1998 Jul; 44():1448. PubMed ID: 9678269
    [No Abstract]   [Full Text] [Related]  

  • 5. MPs' report criticises influence of drugs industry on GP prescribing.
    Kmietowicz Z
    BMJ; 2008 Jan; 336(7636):111. PubMed ID: 18202047
    [No Abstract]   [Full Text] [Related]  

  • 6. Reasons for not seeing drug representatives. Drug representatives have much to offer.
    Benbow AG
    BMJ; 1999 Oct; 319(7215):1003. PubMed ID: 10576841
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors associated with physicians' reliance on pharmaceutical sales representatives.
    Anderson BL; Silverman GK; Loewenstein GF; Zinberg S; Schulkin J
    Acad Med; 2009 Aug; 84(8):994-1002. PubMed ID: 19638762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical representatives.
    Binns TB; Smith A
    Br Med J; 1979 Apr; 1(6171):1134-5. PubMed ID: 444963
    [No Abstract]   [Full Text] [Related]  

  • 9. Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies; Commentary: dramaturgical model gives valuable insight.
    Somerset M; Weiss M; Fahey T
    BMJ; 2001 Dec 22-29; 323(7327):1481-4. PubMed ID: 11751364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reasons for not seeing drug representatives. They should be seen because they are a good resource.
    Tiner R
    BMJ; 1999 Oct; 319(7215):1002. PubMed ID: 10514174
    [No Abstract]   [Full Text] [Related]  

  • 11. Reasons for not seeing drug representatives. But doctors do see them: "freebies" seem disproportionately important.
    Jacobs A
    BMJ; 1999 Oct; 319(7215):1002. PubMed ID: 10576839
    [No Abstract]   [Full Text] [Related]  

  • 12. Reasons for not seeing drug representatives. Companies have to encourage doctors to prescribe their products.
    Dodd P; Dexter T
    BMJ; 1999 Oct; 319(7215):1002-3. PubMed ID: 10576840
    [No Abstract]   [Full Text] [Related]  

  • 13. Interactions between a general practitioner and representatives of drug companies.
    O'Mahony B
    BMJ; 1993 Jun; 306(6893):1649. PubMed ID: 8324433
    [No Abstract]   [Full Text] [Related]  

  • 14. One practice's experiment in refusing detail rep visits.
    Evans DV; Hartung DM; Andeen G; Mahler J; Haxby DG; Kraemer DF; Fagnan LJ
    J Fam Pract; 2011 Aug; 60(8):E1-6. PubMed ID: 21814637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structured approach to pharmaceutical representatives. Family medicine residency program.
    Kelcher S; Brownoff R; Meadows LM
    Can Fam Physician; 1998 May; 44():1053-6, 1059-60. PubMed ID: 9612591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatric resident and faculty views on and interactions with the pharmaceutical industry.
    Misra S; Ganzini L; Keepers G
    Acad Psychiatry; 2010; 34(2):102-8. PubMed ID: 20224017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of interactions between pharmaceutical representatives and ophthalmology trainees.
    Wang Y; Adelman RA
    Am J Ophthalmol; 2009 Oct; 148(4):619-622.e3. PubMed ID: 19570520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dangerous liaisons: doctors-in-training and the pharmaceutical industry.
    Pokorny AM; Gittins CB
    Intern Med J; 2015 Oct; 45(10):1085-8. PubMed ID: 26429220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives.
    Bucci KK; Frey KA
    J Fam Pract; 1992 Jan; 34(1):49-52. PubMed ID: 1728654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residency Curricula on Physician-Pharmaceutical Industry Interaction: A CERA Study.
    Evans DV; Waters RC; Olsen C; Stephens MB; Brown SR
    Fam Med; 2016 Jan; 48(1):44-8. PubMed ID: 26950665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.